SBWire

Global Markets Direct's, 'Dr. Reddy's Laboratories Limited - Product Pipeline Review - 2014', provides an overview of the Dr. Reddy's Laboratories Limited's pharmaceutical research and development focus.

Global Markets Direct's, 'Panacea Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Panacea Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Esperion Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Esperion Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Equine Encephalitis - Pipeline Review, H2 2014', provides an overview of the Equine Encephalitis's therapeutic pipeline.

Global Markets Direct's, 'Bone Marrow Transplantation - Pipeline Review, H2 2014', provides an overview of the Bone Marrow Transplantation's therapeutic pipeline.

GlobalData's clinical trial report, "Lewy body Dementia Global Clinical Trials Review, H1, 2014 provides data on the Lewy body Dementia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lewy body Dementia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lewy body Dementia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Cirrhosis - Pipeline Review, H2 2014', provides an overview of the Cirrhosis's therapeutic pipeline.

The Intercell AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Intercell AG since January 2007.

Global Markets Direct's, 'Epithelial Ovarian Cancer - Pipeline Review, H2 2014', provides an overview of the Epithelial Ovarian Cancer's therapeutic pipeline.

Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded flavivirus most commonly transmitted by the Aedes aegypti (A. aegypti) mosquito. Thought to be responsible for upwards of 100 million infections each year, DENV is the most prevalent arthropod-borne virus in the world. Individuals infected with DENV can present with a wide spectrum of symptoms, including fevers, retro-orbital pain, severe headache, muscle and joint pain, and rash. The severity of dengue fever ranges from asymptomatic cases, to classic dengue fever, and to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) that have a mortality rate of 5%-15%. Because there are no marketed dengue-specific vaccines or therapeutics, current treatment strategies are limited to supportive care for those already infected with the virus, and vector control to reduce DENV transmission. The near-universal failure of these measures to curtain transmission and reduce disease burden across the global marketplace - which for the purposes of this report is comprised of Brazil, India, Mexico, Singapore, and Thailand - has further enhanced the need for safe and effective vaccines. GlobalData expects the launch of the first dengue vaccines, led by Sanofi Pasteur's CYD-TDV and Takeda's DENVax, to revolutionize the treatment and prevention paradigm.

The Wockhardt Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Wockhardt Limited since January 2007.

Global Markets Direct's, 'MediPost Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the MediPost Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Cholera - Pipeline Review, H2 2014', provides an overview of the Cholera's therapeutic pipeline.

GlobalData's clinical trial report, "Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014 provides data on the Intracerebral Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Intracerebral Hemorrhage. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Intracerebral Hemorrhage. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Neonatal Seizures Global Clinical Trials Review, H2, 2014 provides data on the Neonatal Seizures clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neonatal Seizures. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neonatal Seizures. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Japanese encephalitis Global Clinical Trials Review, H1, 2014 provides data on the Japanese encephalitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Japanese encephalitis It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Japanese encephalitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Mastalgia (Breast Pain) Global Clinical Trials Review, H1, 2014 provides data on the Mastalgia (Breast Pain) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mastalgia (Breast Pain). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mastalgia (Breast Pain). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Aventis SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Aventis SA since January 2007.

GlobalData's clinical trial report, "Encephalopathy Global Clinical Trials Review, H1, 2014 provides data on the Encephalopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Encephalopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Encephalopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Quadriplegia / Tetraplegia Global Clinical Trials Review, H1, 2014 provides data on the Quadriplegia / Tetraplegia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Quadriplegia / Tetraplegia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Quadriplegia / Tetraplegia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Phobia Global Clinical Trials Review, H1, 2014 provides data on the Phobia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Phobia It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Phobia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA.

Global Markets Direct's, 'bluebird bio, Inc. - Product Pipeline Review - 2014', provides an overview of the bluebird bio, Inc.'s pharmaceutical research and development focus.

Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.

GlobalData's clinical trial report, "Paraplegia Global Clinical Trials Review, H1, 2014 provides data on the Paraplegia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Paraplegia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Paraplegia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.